Heat Biologics Inc., of Durham, N.C., started dosing in its phase II trial of viagenpumatucel-L (HS-110) in patients with non-small-cell lung cancer. HS-110 is Heat's most advanced product candidate in a series of Immune Pan Antigen Cytotoxic Therapy compounds based allogeneic cell lines designed to direct killer T cells to attack cancer.